Ratings Novartis AG Nyse

Equities

NVS

US66987V1098

Market Closed - Nyse Other stock markets 04:00:02 2024-04-26 pm EDT			5-day change	1st Jan Change
97.44 ^USD	-1.64%		+3.26%	-3.50%

Apr. 26	NOVARTIS AG : Receives a Buy rating from Jefferies	ZD
Apr. 24	BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
With an enterprise value anticipated at 4 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
NOVARTIS AG	-3.50%	200B	-
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+
PFIZER, INC.	-11.77%	144B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes